NCT07811089

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-09Est. Completion: 2027-05

Enrollment target: 84 participants

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacok…

Pasadena, United StatesCompleted Aug 22, 2025

Congenital Adrenal Hyperplasia

The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 mo…

San Francisco, United StatesEst. completion Mar 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.